AAAAAA
Results: 26-44/44
Authors:
MCMURROUGH J
MCLEOD HL
Citation: J. Mcmurrough et Hl. Mcleod, ANALYSIS OF THE DIHYDROPYRIMIDINE DEHYDROGENASE POLYMORPHISM IN A BRITISH POPULATION, British journal of clinical pharmacology, 41(5), 1996, pp. 425-427
Authors:
MCLEOD HL
KUMAR A
Citation: Hl. Mcleod et A. Kumar, METABOLISM OF AZATHIOPRINE, Transplantation, 61(9), 1996, pp. 1425-1425
Authors:
WEI XX
MCLEOD HL
MCMURROUGH J
GONZALEZ FJ
FERNANDEZSALGUERO P
Citation: Xx. Wei et al., MOLECULAR-BASIS OF THE HUMAN DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY AND 5-FLUOROURACIL TOXICITY, The Journal of clinical investigation, 98(3), 1996, pp. 610-615
Authors:
MCLEOD HL
KEITH WN
Citation: Hl. Mcleod et Wn. Keith, VARIATION IN TOPOISOMERASE-I GENE COPY NUMBER AS A MECHANISM FOR INTRINSIC DRUG-SENSITIVITY, British Journal of Cancer, 74(4), 1996, pp. 508-512
Authors:
MCLEOD HL
MURRAY LS
WANDERS J
SETANOIANS A
GRAHAM MA
PAVLIDIS N
HEINRICH B
HUININK WWT
WAGENER DJT
AAMDAL S
VERWEIJ J
Citation: Hl. Mcleod et al., MULTICENTER PHASE-II PHARMACOLOGICAL EVALUATION OF RHIZOXIN, British Journal of Cancer, 74(12), 1996, pp. 1944-1948
Authors:
MCLEOD HL
BRUNTON VG
ECKARDT N
LEAR MJ
ROBINS DJ
WORKMAN P
GRAHAM MA
Citation: Hl. Mcleod et al., IN-VIVO PHARMACOLOGY AND ANTITUMOR EVALUATION OF THE TYRPHOSTIN TYROSINE KINASE INHIBITOR RG13022, British Journal of Cancer, 74(11), 1996, pp. 1714-1718
Authors:
MCLEOD HL
KRYNETSKI EY
WILIMAS JA
EVANS WE
Citation: Hl. Mcleod et al., HIGHER ACTIVITY OF POLYMORPHIC THIOPURINE S-METHYLTRANSFERASE IN ERYTHROCYTES FROM NEONATES COMPARED TO ADULTS, Pharmacogenetics, 5(5), 1995, pp. 281-286
Authors:
MCLEOD HL
Citation: Hl. Mcleod, COMMENTARY ON INTERACTIONS BETWEEN 6-MERCAPTOPURINE THERAPY AND THIOPURINE-METHYL-TRANSFERASE (TPMT) ACTIVITY, European Journal of Clinical Pharmacology, 48(1), 1995, pp. 85-86
Authors:
MCLEOD HL
RELLING MV
LIU Q
PUI CH
EVANS WE
Citation: Hl. Mcleod et al., POLYMORPHIC THIOPURINE METHYLTRANSFERASE IN ERYTHROCYTES IS INDICATIVE OF ACTIVITY IN LEUKEMIC BLASTS FROM CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA, Blood, 85(7), 1995, pp. 1897-1902
Authors:
MCLEOD HL
Citation: Hl. Mcleod, CLINICAL REVERSAL OF THE MULTIDRUG-RESISTANCE PHENOTYPE - TRUE TUMOR MODULATION OR PHARMACOKINETIC INTERACTION, European journal of cancer, 30A(14), 1994, pp. 2039-2041
Authors:
HOLLANDER D
PRADAS J
KAPLAN R
MCLEOD HL
EVANS WE
MUNSAT TL
Citation: D. Hollander et al., HIGH-DOSE DEXTROMETHORPHAN IN AMYOTROPHIC-LATERAL-SCLEROSIS - PHASE-ISAFETY AND PHARMACOKINETIC STUDIES, Annals of neurology, 36(6), 1994, pp. 920-924
ETHNIC-DIFFERENCES IN ERYTHROCYTE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN BLACK-AND-WHITE AMERICANS
Authors:
MCLEOD HL
FANG L
LUO XL
SCOTT EP
EVANS WE
Citation: Hl. Mcleod et al., ETHNIC-DIFFERENCES IN ERYTHROCYTE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN BLACK-AND-WHITE AMERICANS, The Journal of pharmacology and experimental therapeutics, 270(1), 1994, pp. 26-29
Authors:
MCLEOD HL
DOUGLAS F
OATES M
SYMONDS RP
PRAKASH D
VANDERZEE AGJ
KAYE SB
BROWN R
KEITH WN
Citation: Hl. Mcleod et al., TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITY IN HUMAN BREAST, CERVIX, LUNG AND COLON-CANCER, International journal of cancer, 59(5), 1994, pp. 607-611
Authors:
RELLING MV
MCLEOD HL
BOWMAN LC
SANTANA VM
Citation: Mv. Relling et al., ETOPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS AFTER ACUTE AND CHRONIC EXPOSURE TO CISPLATIN, Clinical pharmacology and therapeutics, 56(5), 1994, pp. 503-511
Authors:
MCLEOD HL
Citation: Hl. Mcleod, CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6, Clinical pharmacology and therapeutics, 56(4), 1994, pp. 463-463
Authors:
MCLEOD HL
LIN JS
SCOTT EP
PUI CH
EVANS WE
Citation: Hl. Mcleod et al., THIOPURINE METHYLTRANSFERASE ACTIVITY IN AMERICAN WHITE SUBJECTS AND BLACK SUBJECTS, Clinical pharmacology and therapeutics, 55(1), 1994, pp. 15-20
Authors:
MCLEOD HL
EVANS WE
Citation: Hl. Mcleod et We. Evans, CLINICAL PHARMACOKINETICS AND PHARMACODYNAMICS OF EPIPODOPHYLLOTOXINS, Cancer surveys, 17, 1993, pp. 253-268
Authors:
MCLEOD HL
MILLER DR
EVANS WE
Citation: Hl. Mcleod et al., AZATHIOPRINE-INDUCED MYELOSUPPRESSION IN THIOPURINE METHYLTRANSFERASEDEFICIENT HEART-TRANSPLANT RECIPIENT, Lancet, 341(8853), 1993, pp. 1151-1151
Authors:
EVANS WE
RELLING MV
RAHMAN A
MCLEOD HL
SCOTT EP
LIN JS
Citation: We. Evans et al., GENETIC-BASIS FOR A LOWER PREVALENCE OF DEFICIENT CYP2D6 OXIDATIVE DRUG-METABOLISM PHENOTYPES IN BLACK-AMERICANS, The Journal of clinical investigation, 91(5), 1993, pp. 2150-2154